Can Patches Improve Vaccination Rates?

Microneedle array patches (MAP), which have previously been used for cosmetics applications, are being considered for delivering a variety of vaccines. Earlier this year Harro Höfliger and PATH hosted a conference exploring such opportunities that drew representatives of the World Health Organization (WHO), UNICEF, the Bill &Melinda Gates Foundation, the Vaccine Alliance Gavi, and other researchers. The group is working to improve vaccination levels in low- and middle-income countries, particularly those for measles and rubella but also for other diseases, Stefan Bernsau, director, needle technology for Harro Höfliger, told MD+DI. The MAP technology offers such a potential because microneedles can pierce the dermis at a depth of about 250 – 300 micrometers, explained Bernsau. “The microneedles will release the drug inside the dermis, which is rich in immune cells,” he said. Bernsau said there are several big advantages in MAP technology. “Due to the fact that the vaccine or the drugs are in a dry solid state, MAPs do not require a cold chain for the vaccine. This is a huge benefit, especially in the LMIC (low- and middle-income countries). But it is also an advantage in the high-developed countries. No cold chain means significant savings in the delivery of vaccines and drugs,” he said. “Another advantage is the fact that the MAP technology...
Source: MDDI - Category: Medical Devices Authors: Tags: R & D Source Type: news

Related Links:

Experts say the policy prompts people happy to vaccinate their children but doesn ’t work on those who oppose vaccination scienceAustralia ’s “no jab, no pay” policy has been associated with a drop in the number of children catching up on their first dose of the measles, mumps and rubella vaccine, suggesting the policy has had little impact on those who reject vaccination science.However, the policy was associated with more children catching up on their second dose of the vaccine and on their diphtheria –tetanus–pertussis vaccine, especially in lower socioeconomic status areas, the study...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Health Vaccines and immunisation Science Australia news Source Type: news
We report a child homozygous for a genomic deletion of the entire coding sequence and part of the 3’U TR of the last exon of IFNAR1, who died from HSE at the age of two years. An older cousin died following vaccination against measles, mumps and rubella at 12 months of age, and another 17-year-old cousin homozygous for the same variant has had other viral illnesses. The encoded IFNAR1 protein is exp ressed on the cell surface but is truncated and cannot interact with the tyrosine kinase TYK2. The patient’s fibroblasts and EBV-B cells did not respond to IFN-α2b or IFN-β, in terms of STAT1, STAT2 and S...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
Measles (rubeola) is a highly contagious infectious disease with significant morbidity/mortality. Measles-Mumps-Rubella (MMR) is a live-attenuated vaccine used in the United States (US) to prevent measles. This retrospective longitudinal cohort study evaluated childhood MMR vaccination and the risk of a seizure episode and seizure disorder.
Source: Brain and Development - Category: Neurology Authors: Tags: Original article Source Type: research
CONCLUSIONS: Linking family assistance payments with childhood vaccination status and associated program improvements were followed by substantial catch-up vaccination activity, particularly in young people from families of lower socio-economic status. PMID: 32951230 [PubMed - as supplied by publisher]
Source: Med J Aust - Category: General Medicine Authors: Tags: Med J Aust Source Type: research
r U Abstract Measles outbreaks occur rather frequently in Germany. Patients with chronic inflammatory diseases are often treated with immunosuppressants. A recent study showed that about 7% of such patients are not protected against measles according to the lack of documentation in the vaccination card or the absence of protective antibodies. The Standing Committee on Immunization (STIKO) recommends a first vaccination against measles as a measles-mumps-rubella combined vaccination (MMR) in children aged 11-14 months and a second vaccination at 14-23 months. For adults born after 1970, vaccination against measles ...
Source: Zeitschrift fur Rheumatologie - Category: Rheumatology Authors: Tags: Z Rheumatol Source Type: research
History illustrates the remarkable public health impact of mass vaccination, by dramatically improving life expectancy and reducing the burden of infectious diseases and co-morbidities worldwide. It has been perceived that if an individual adhered to the MMR vaccine schedule that immunity to mumps virus (MuV) would be lifelong. Recent mumps outbreaks in individuals who had received two doses of the Measles Mumps Rubella (MMR) vaccine has challenged the efficacy of the MMR vaccine. However, clinical symptoms, complications, viral shedding and transmission associated with mumps infection has been shown to be reduced in vacci...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
We describe a 2 year old boy with two previously undescribed frameshift mutations in the interferon (IFN)α/β receptor 2 (IFNAR2) gene presenting with hemophagocytic lymphohistiocytosis (HLH) following measles-mumps-rubella vaccination. Functional analyses show the absence of response to type I IFN in the patient’s cells, as revealed by the lack of phosphorylation of STAT1 and the lack of induction of interferon-stimulated genes upon ex vivo stimulation with IFNα. HLH has been reported in patients with inborn errors of type I IFN-mediated immune responses following vaccination with live-attenuated vir...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
CONCLUSIONS: The misleading vaccine autism controversy must be set aside in favor of examining actual neurological harms associated with vaccines, including building on existing research that has been ignored. Manufacturers of vaccines must be required to conduct placebo-controlled clinical studies for existing vaccines and for government approval of new vaccines. Many probable or confirmed neurological adverse events occur within a few days or weeks after immunization and could be detected if the trials were sufficiently large. Contrary to current opinion, large, long-term placebo-controlled trials of existing and new vac...
Source: International Journal of Risk and Safety in Medicine - Category: Drugs & Pharmacology Tags: Int J Risk Saf Med Source Type: research
A new clinical trial will try to determine whether the measles, mumps and rubella (MMR) vaccine can protect health care workers from being infected with COVID-19.
Source: WebMD Health - Category: Consumer Health News Source Type: news
FRIDAY, Sept. 4, 2020 -- A new clinical trial will try to determine whether the measles, mumps and rubella (MMR) vaccine can protect health care workers from being infected with COVID-19. Hundreds of millions of people have received the MMR vaccine...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
More News: Child Development | Children | Conferences | Hospitals | International Medicine & Public Health | Learning | Measles | Measles Vaccine | Medical Devices | Rubella | Rubella Vaccine | Study | Universities & Medical Training | Vaccines | WHO | Workshops